Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

C4 Therapeutics

C4 Therapeutics
2015 FOUNDED
PRIVATE STATUS
Series A LATEST DEAL TYPE
$73M LATEST DEAL AMOUNT
7 INVESTORS
Description

Developer of drugs designed to provide treatment for cancer, cardiovascular, gastrointestinal and central nervous system diseases. The company develops synthetic chemical compounds to bind with disease-causing proteins and and flag them as cellular trash to get rid of them, enabling patients to begin treatment more quickly and result in a higher likelihood of a successful treatment.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Other Pharmaceuticals and Biotechnology
Primary Office
  • 675 West Kendall Street
  • Cambridge, MA 02142
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore C4 Therapeutics’s full profile, request a free trial.

C4 Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 29-Dec-2015 $73M 0000 00000 Completed Startup
1. Early Stage VC 30-Nov-2015 000 000 000.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

C4 Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 000,000,000 00.000000 00.00 00 00 00 00 00.000
Seed 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
FF Preferred 32,760,000 $0.000500 $0 $0 1x $0 26.63%
To view this company’s complete Cap Table, request access »

C4 Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Cobro Ventures Angel Group Minority 000 0000 000000 0
Cormorant Asset Management Hedge Fund Minority 000 0000 000000 0
EG Capital Group PE/Buyout Minority 000 0000 000000 0
Norda Stelo Corporation Minority 000 0000 000000 0
Novartis Corporation Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

C4 Therapeutics Executive Team (12)

Name Title Board
Seat
Contact
Info
Andrew Phillips Chief Executive Officer
Jane Farran Ph.D Managing Partner
Stewart Fisher Ph.D Chief Scientific Officer
Nathanael Gray Ph.D Co-Founder & Scientific Advisory Board Member
James Bradner MD Scientific Co-Founder

3 Former Executives

You’re viewing 5 of 12 executives. Get the full list »

C4 Therapeutics Board Members (14)

Name Representing Role Since Contact
Info
Alain Cohen Cobro Ventures Board Member 000 0000
Bihua Chen Cormorant Asset Management Board Member 000 0000
Bruce Downey JD Self Board Member 000 0000
Elena Prokupets Ph.D Self Board Member 000 0000
Jay Eastman Ph.D EG Capital Group Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 14 board members. Get the full list »